Molecular Diagnostics Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 747 Deals Signed Since 2016 by Company A-Z, Financial Terms, Deal Type and Therapy Area - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Molecular Diagnostics Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 747 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties.

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

• Understand deal trends since 2016
• Browse molecular diagnostics collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2024. The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

Report Scope

Molecular Diagnostics Collaboration and Licensing Deals includes:

• Trends in molecular diagnostics dealmaking in the biopharma industry
• Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
• The leading molecular diagnostics deals by value
• Most active molecular diagnostics licensing dealmakers

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

2.1. Introduction

2.2. Molecular diagnostics deals over the years

2.3. Most active molecular diagnostics dealmakers

2.4. Molecular diagnostics deals by deal type

2.5. Molecular diagnostics deals by therapy area

2.6. Molecular diagnostics deals by industry sector

2.7. Deal terms for molecular diagnostics deals

2.7.1 Molecular diagnostics deals headline values

2.7.2 Molecular diagnostics deal upfront payments

2.7.3 Molecular diagnostics deal milestone payments

2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

3.1. Introduction

3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

4.1. Introduction

4.2. Most active molecular diagnostics dealmakers

4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

5.1. Introduction

5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

Deal directory

Deal directory - Molecular diagnostics deals by company A-Z

Deal directory - Molecular diagnostics deals by deal type

Deal directory - Molecular diagnostics deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/480x05

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.